Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has been given a consensus rating of “Buy” by the six analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $26.00.
Several analysts have recently issued reports on the company. ValuEngine upgraded Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 5th. Zacks Investment Research upgraded Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a research note on Thursday, January 3rd.
A number of large investors have recently made changes to their positions in AGLE. Cubist Systematic Strategies LLC bought a new stake in Aeglea Bio Therapeutics during the 2nd quarter valued at approximately $131,000. Rhumbline Advisers bought a new stake in Aeglea Bio Therapeutics during the 2nd quarter valued at approximately $161,000. AQR Capital Management LLC boosted its stake in Aeglea Bio Therapeutics by 42.0% during the 3rd quarter. AQR Capital Management LLC now owns 28,297 shares of the biotechnology company’s stock valued at $271,000 after purchasing an additional 8,376 shares during the period. Schwab Charles Investment Management Inc. bought a new stake in Aeglea Bio Therapeutics during the 2nd quarter valued at approximately $321,000. Finally, Bank of New York Mellon Corp bought a new stake in Aeglea Bio Therapeutics during the 2nd quarter valued at approximately $438,000. Hedge funds and other institutional investors own 61.13% of the company’s stock.
Shares of AGLE traded down $0.05 during trading hours on Monday, hitting $8.51. 57,543 shares of the company were exchanged, compared to its average volume of 97,613. The company has a market cap of $207.03 million, a PE ratio of -4.73 and a beta of 0.86. Aeglea Bio Therapeutics has a 52 week low of $5.12 and a 52 week high of $12.00.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.10). Aeglea Bio Therapeutics had a negative return on equity of 62.12% and a negative net margin of 480.92%. On average, research analysts predict that Aeglea Bio Therapeutics will post -1.86 EPS for the current year.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Recommended Story: What is a Swap?
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.